Median age,
|
Years [range]
|
58 [26–81]
|
-
|
63 [14–83]
|
-
|
Gender
|
|
|
|
|
|
|
Male
|
52
|
43.7
|
38
|
55.9
|
Female
|
67
|
56.3
|
30
|
44.1
|
Histology
|
|
|
|
|
|
|
Thymomas
|
119
|
100.0
|
|
|
Type A
|
5
|
4.2
|
Type B1
|
19
|
16.1
|
Type B2
|
39
|
32.8
|
Type B3
|
15
|
12.6
|
Type AB
|
33
|
27.7
|
Other subtypes or missing data of thymoma
|
8
|
6.7
|
|
Thymic carcinomas
|
|
|
68
|
100.0
|
Squamous cell carcinoma
|
|
|
46
|
67.6
|
Mucoepidermoid carcinoma
|
|
|
5
|
7.4
|
Lymphoepithelioma-like carcinoma
|
|
|
1
|
1.5
|
Undifferentiated carcinoma
|
|
|
3
|
4.4
|
Neuroendocrine carcinomas
|
|
|
11
|
16.2
|
Small cell carcinoma
|
|
|
3
|
4.4
|
LCNEC
|
|
|
2
|
2.9
|
Carcinoid
|
|
|
6
|
8.8
|
Not classified in WHO classification
|
|
|
2
|
2.9
|
Staging
|
|
|
|
|
|
|
I
|
52
|
43.7
|
0
|
0
|
II
|
31
|
26.1
|
6
|
8.8
|
III
|
12
|
10.1
|
10
|
14.7
|
IVa
|
18
|
15.1
|
16
|
23.5
|
IVb
|
6
|
5.0
|
36
|
52.9
|
Complications
|
|
|
|
|
|
|
Immunological abnormalities (overlapped)
|
|
|
|
|
Myasthenia gravis
|
20
|
16.8
|
1
|
1.5
|
Pure red cell aplasia
|
4
|
3.3
|
|
|
Hypogammaglobulinemia
|
5
|
4.2
|
|
|
Secondary malignancies
|
12
|
10.1
|
13
|
19.1
|
Initial treatment-intent of modalities
|
|
|
|
|
|
Curative-intent treatment
|
116
|
97.5
|
43
|
63.2
|
|
Surgery
|
109
|
91.6
|
30
|
44.1
|
|
Surgery alone
|
89
|
74.8
|
10
|
14.7
|
Surgery with perioperative treatment
|
20
|
16.8
|
20
|
29.4
|
|
Radiotherapy
|
7
|
5.9
|
13
|
19.1
|
|
Definitive radiotherapy alone
|
1
|
0.8
|
1
|
1.5
|
Chmoradiotherapy (sequential/concurrent)
|
6
|
5.1
|
12
|
17.6
|
|
Palliative-intent treatment
|
3
|
2.5
|
25
|
36.8
|
|
Chemotherapy alone
|
2
|
1.7
|
24
|
35.3
|
|
Best supportive care |
1 |
0.8 |
1 |
1.5 |